Celldex presents results from Barzolvolimab Phase 2 Study in ColdU, SD

Celldex (CLDX) announced new data demonstrating sustained efficacy and a well tolerated safety profile over a 20 week treatment period for barzolvolimab in two of the most common forms of chronic inducible urticaria-cold urticaria, ColdU, and symptomatic dermographism, SD. The data is being presented at the American College of Allergy, Asthma & Immunology’s Annual Scientific Meeting in Orlando, Florida. Summary of Phase 2 data as assessed at end of 20 week placebo controlled treatment period: Up to 66% of patients with ColdU and 49% of patients with SD obtained a complete response compared to 16% and 10% of patients on placebo, respectively. Up to 78% of patients with ColdU and 58% of patients with SD obtained a partial or complete response compared to 25% and 16% of patients on placebo, respectively.